Dupixent Injection, Solution
Product Images NDC 0024-5915

142 FDA label images from Sanofi-aventis U.s. Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 142 technical images submitted to the FDA as part of the official labeling for Dupixent (NDC 0024-5915). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sanofi-aventis U.s. Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Dupixent 01)

Figure 1 (Dupixent 01)
A line graph comparing the proportion of subjects (%) over 16 weeks between DUPIXENT 300 mg administered every two weeks (Q2W) and placebo groups. The graph shows a steadily increasing response in the DUPIXENT group reaching 40.8% at week 16, versus 12.3% in the placebo group.*
FDA Label Image

Figure 2 (Dupixent 02)

Figure 2 (Dupixent 02)
A line graph comparing the proportion of subjects (%) over time (weeks) between Dupixent 300 mg Q2W (225 subjects) and placebo (221 subjects). The graph shows higher proportions for Dupixent, reaching 36.0% at 16 weeks, versus 9.5% for placebo.*
FDA Label Image

Figure 3 (Dupixent 03)

Figure 3 (Dupixent 03)
A line graph comparing the proportion of subjects (%) over 16 weeks between two groups: Dupixent (Dupilumab) 200 mg or 300 mg every two weeks and placebo. The Dupixent group shows an increase to 36.6%, while the placebo group remains near 4.8%. The graph illustrates treatment response over time in a study with 82 subjects on Dupixent and 85 on placebo.*
FDA Label Image

Figure 4 (Dupixent 04)

Figure 4 (Dupixent 04)
A bar chart showing the proportion of subjects (%) by weight group treated with Dupilumab plus TCS versus placebo plus TCS. For subjects under 30 kg, Dupilumab 300 mg every 4 weeks shows a 54.1% response compared to 11.7% for placebo. For subjects 30 kg or greater, Dupilumab 200 mg every 2 weeks shows a 61.4% response compared to 12.9% for placebo.*
FDA Label Image

Figure 5 (Dupixent 05)

Figure 5 (Dupixent 05)
A forest plot chart showing the rate ratio of Dupixent 200 mg and 300 mg administered every two weeks versus placebo across baseline blood eosinophil groups. The chart compares overall and subgroup rate ratios with 95% confidence intervals, indicating Dupixent's relative effect compared to placebo.*
FDA Label Image

Figure 6 (Dupixent 06)

Figure 6 (Dupixent 06)
A forest plot showing rate ratios comparing Dupixent 300 mg Q2W and 200 mg Q2W to placebo across different baseline FeNO groups. The graph presents overall results and subgroups with FeNO levels ≥25 ppb and <25 ppb, including sample sizes and 95% confidence intervals indicating efficacy results of Dupixent versus placebo.*
FDA Label Image

Figure 6 (Dupixent 07)

Figure 6 (Dupixent 07)
A line graph showing the probability of event (%) over time (weeks) comparing Dupixent 300 mg and 200 mg administered every two weeks (Q2W) versus placebo groups. The graph includes data points and error bars with numerical risk counts at various weeks for each treatment group.*
FDA Label Image

Figure 6 (Dupixent 08)

Figure 6 (Dupixent 08)
A chart showing least squares (LS) mean difference with 95% confidence intervals comparing Dupixent 300 mg and 200 mg every two weeks versus placebo. The horizontal axis shows LS mean difference from -0.25 to 0.5, with a vertical line at zero separating placebo better and Dupixent better. Five groups are shown by baseline blood eosinophil counts (cells/mcL): Overall, ≥500, ≥300 - <500, ≥150 - <300, and <150, with sample sizes and LS mean difference values presented for each group. Dupixent 300 mg doses are represented by squares and Dupixent 200 mg doses by circles.*
FDA Label Image

Figure 6 (Dupixent 09)

Figure 6 (Dupixent 09)
A forest plot showing LS mean differences with 95% confidence intervals comparing Dupixent 300 mg and 200 mg every 2 weeks versus placebo across overall, baseline FeNO ≥25, and baseline FeNO <25 groups. The horizontal axis indicates LS mean difference favoring placebo on the left and Dupixent on the right. Numeric group sizes and confidence intervals accompany each comparison.*
FDA Label Image

Figure 10 (Dupixent 10)

Figure 10 (Dupixent 10)
A line graph showing least squares mean change in liters (L) with standard error over 52 weeks for Dupixent at 200 mg and 300 mg doses administered every 2 weeks (Q2W) compared to placebo groups. The y-axis represents change in liters, and the x-axis represents time in weeks, illustrating sustained improvements for both Dupixent doses versus placebo over one year.*
FDA Label Image

Figure 11 (Dupixent 11)

Figure 11 (Dupixent 11)
Line graph showing the least squares mean change in pEFV over 52 weeks comparing Dupixent (N=175) to placebo (N=84). The x-axis represents weeks from 0 to 52 and the y-axis indicates change values with error bars representing standard error. Dupixent shows a higher increase in pEFV over time, reaching approximately 12.43, while placebo peaks around 4.08.*
FDA Label Image

Figure 12 (Dupixent 11a)

Figure 12 (Dupixent 11a)
A line graph comparing the least squares mean change with standard error over 52 weeks between Dupixent 300 mg administered every two weeks and placebo. The vertical axis represents LS mean change +/- SE, and the horizontal axis displays time in weeks. Dupixent shows a notable decreasing trend over time, while placebo remains near zero.*
FDA Label Image

Figure 13 (Dupixent 11b)

Figure 13 (Dupixent 11b)
A line graph comparing LS mean change over weeks between Dupixent 300 mg Q2W (every two weeks) and placebo groups. The x-axis represents weeks from 0 to 48, and the y-axis shows LS mean change ± SE. Data points for Dupixent show a decrease below zero over 24 weeks and partial recovery in the post-treatment period (weeks 24 to 48), while placebo data remain near zero throughout.*
FDA Label Image

Figure 14 (Dupixent 11c)

Figure 14 (Dupixent 11c)
Kaplan-Meier plot showing the probability of an event over 52 weeks comparing DUPIXENT 300 mg administered every two weeks (Q2W) with placebo administered every two weeks. The y-axis represents the probability of the event in percentage, and the x-axis shows time in weeks. A table below the graph displays the number of patients at risk at various time points for both groups.*
FDA Label Image

Figure 15 (Dupixent 11d)

Figure 15 (Dupixent 11d)
A line graph depicting the proportion of subjects (%) over 24 weeks in a clinical study comparing Dupixent 300 mg Q2W with placebo. The graph includes data from PRIME and PRIME 2 trials, showing higher subject proportions for Dupixent groups compared to placebo groups over time.*
FDA Label Image

Figure 16 (Dupixent 11e)

Figure 16 (Dupixent 11e)
A line graph depicting the proportion of subjects (%) over weeks (0 to 24) comparing DUPIXENT 300 mg given every 2 weeks with placebo groups in the PRIME and PRIME 2 studies. The graph shows higher subject proportions in the DUPIXENT groups versus placebo over time, with values noted at week 24.*
FDA Label Image

Figure 17 (Dupixent 11f)

Figure 17 (Dupixent 11f)
Two line graphs depicting the least squares mean change with 95% confidence intervals over 52 weeks. The left graph compares Dupixent 300 mg every two weeks versus placebo in the BOREAS study. The right graph presents similar data for the NOTUS study with comparable groups and dosages.*
FDA Label Image

Figure 18 (Dupixent 11g)

Figure 18 (Dupixent 11g)
A line graph comparing the change in ISS7 least squares mean scores with standard error between Dupixent and placebo groups over 24 weeks. The x-axis represents time in weeks, and the y-axis shows ISS7 LS mean change. Dupixent shows a greater decrease over time compared to placebo.*
FDA Label Image

Figure 18 (Dupixent 11h)

Figure 18 (Dupixent 11h)
A line graph showing the least-squares mean change with standard error in ISS7 scores over 24 weeks comparing Dupixent (73 participants) versus placebo (75 participants). The Y-axis represents ISS7 mean change, and the X-axis represents weeks, indicating Dupixent results in a greater reduction over time compared to placebo.*
FDA Label Image

Figure 19 (Dupixent 11i)

Figure 19 (Dupixent 11i)
A line graph comparing LS mean change plus or minus standard error (SE) over 52 weeks between Dupixent (N=33) and placebo (N=29) groups. The x-axis represents weeks from baseline (BL) to 52 weeks, and the y-axis shows LS mean change ranging from 0.0 to -1.5. Dupixent shows a decreasing trend over time, whereas placebo remains near baseline with minor fluctuations.*
FDA Label Image

Figure 20 (Dupixent 11j)

Figure 20 (Dupixent 11j)
A line graph comparing the least squares mean change with standard error from baseline over 52 weeks between Dupixent and placebo groups. The x-axis shows time in weeks (BL, 12, 24, 36, 52) and the y-axis shows LS mean change. Dupixent shows a greater decrease over time compared to placebo, which remains relatively stable.*
FDA Label Image

Image (Dupixent 12)

Image (Dupixent 12)
An instructional diagram showing a syringe before and after use. The pre-use syringe includes labeled parts: plunger rod, finger grip, label, viewing window, syringe body, needle, and needle cap. The post-use syringe image shows the plunger rod pushed down with the needle exposed and a needle shield surrounding the needle.*
FDA Label Image

Image (Dupixent 13)

FDA Label Image

Image (Dupixent 14)

Image (Dupixent 14)
An instructional illustration showing a hand holding the Dupixent prefilled syringe inside an open cardboard box. The box contains foil pouches or packaging slots for organizing the medication components.*
FDA Label Image

Image (Dupixent 15)

Image (Dupixent 15)
An instructional illustration showing the contents included with the Dupixent pre-filled syringe package: one pre-filled syringe, one alcohol wipe, one cotton ball or gauze, and one sharps disposal container.*
FDA Label Image

Image (Dupixent 16)

Image (Dupixent 16)
Illustration showing the location of the expiration date label on a Dupixent prefilled syringe, highlighting where to find the lot number and expiration date information on the device.*
FDA Label Image

Image (Dupixent 17)

Image (Dupixent 17)
An instructional diagram showing the Dupixent prefilled syringe with a focus on the viewing window. The image demonstrates how to hold the syringe to observe the label through the viewing window. Dupixent is available in strengths of 200 mg/1.14 mL and 300 mg/2 mL, labeled by Sanofi-Aventis U.S. LLC.*
FDA Label Image

Image (Dupixent 18)

Image (Dupixent 18)
An instructional illustration showing an injection syringe with a timer set to 45 minutes, likely indicating a recommended wait or procedure time related to the use of Dupixent injectable product.*
FDA Label Image

Image (Dupixent 19)

Image (Dupixent 19)
Illustration showing recommended injection sites for Dupixent. Light blue areas on the abdomen and thighs indicate sites for self-injection or caregiver administration. Dark blue areas on the upper arms indicate sites for injection by caregiver only.*
FDA Label Image

Image (Dupixent 20)

Image (Dupixent 20)
An instructional illustration showing a person's hand applying a small rectangular patch to the skin on the lower abdomen, near the waistline. The image suggests the procedure of placing a transdermal or topical patch.*
FDA Label Image

Image (Dupixent 21)

Image (Dupixent 21)
An instructional illustration showing hands preparing a syringe injection device, likely related to Dupixent. The image demonstrates holding the syringe with one hand and removing or adjusting a component with the other, indicated by bidirectional arrows to show motion.*
FDA Label Image

Image (Dupixent 22)

Image (Dupixent 22)
An instructional illustration showing a person pinching the skin on the abdomen with their fingers, likely demonstrating how to prepare the injection site for administering Dupixent by subcutaneous injection.*
FDA Label Image

Image (Dupixent 23)

Image (Dupixent 23)
An instructional diagram showing the proper technique for administering an injection at a 45-degree angle into the skin. The illustration depicts a hand inserting a syringe into the skin, suggesting the positioning and angle for the injection.*
FDA Label Image

Image (Dupixent 24)

Image (Dupixent 24)
An instructional illustration showing the administration of a Dupixent injection using a prefilled syringe or auto-injector device. It depicts a hand holding the device positioned to inject into the abdominal area, demonstrating proper injection technique.*
FDA Label Image

Image (Dupixent 25)

Image (Dupixent 25)
An instructional illustration showing a hand holding a prefilled syringe or injector pen near a person’s abdomen, indicating the step of preparing for an injection by positioning the device against the skin. The image uses arrow and hand placement to demonstrate the technique.*
FDA Label Image

Image (Dupixent 26)

Image (Dupixent 26)
Instructional illustration showing a hand placing a syringe labeled 'Syringe' into a sharps disposal container. The container is marked with 'Sharps Disposal Container' and the lid has a labeled area for 'Needle Cap.' It demonstrates safe disposal of used syringes.*
FDA Label Image

Logo (Dupixent 26a)

FDA Label Image

Image (Dupixent 27)

Image (Dupixent 27)
An instructional diagram showing the Dupixent syringe before and after use. The 'Before Use' side labels the plunger rod, finger grip, viewing window, syringe body, needle, and needle cap. The 'After Use' side labels the plunger rod, finger grip, needle, and needle shield, depicting the syringe with the plunger fully depressed and the needle shield engaged.*
FDA Label Image

Image (Dupixent 28)

FDA Label Image

Image (Dupixent 29)

Image (Dupixent 29)
An instructional illustration showing a hand holding a Dupixent prefilled syringe inside an open box, displaying the syringe and the organized compartments within the packaging.*
FDA Label Image

Image (Dupixent 30)

Image (Dupixent 30)
An instructional illustration related to Dupixent pre-filled syringe, showing the required items for administration: 1 alcohol wipe, 1 cotton ball or gauze, and a sharps disposal container. The image includes simple icons representing each item for clarity.*
FDA Label Image

Image (Dupixent 31)

Image (Dupixent 31)
An instructional diagram showing how to locate the expiration date on the Dupixent prefilled syringe. The image highlights the side of the syringe barrel, indicating where the lot number and expiration date are printed on the label.*
FDA Label Image

Image (Dupixent 32)

Image (Dupixent 32)
An instructional diagram of a Dupixent prefilled syringe showing a viewing window that displays the lot number and expiration date. The syringe is depicted with a label indicating where to check these details before use.*
FDA Label Image

Image (Dupixent 33)

Image (Dupixent 33)
An instructional illustration depicting a syringe with a plunger and needle cap. Next to the syringe is a clock graphic indicating a 30-minute wait time, suggesting a post-injection waiting period or preparation time.*
FDA Label Image

Image (Dupixent 34)

Image (Dupixent 34)
An illustration showing recommended injection sites on a human body for Dupixent. Blue areas indicate sites for self-injection or injection by a caregiver, including the front thighs and abdomen. Dark blue areas on the upper arms indicate injection sites by a caregiver only.*
FDA Label Image

Image (Dupixent 35)

Image (Dupixent 35)
Instructional illustration showing a hand applying a small adhesive patch to the lower abdominal area, potentially demonstrating part of the application process for the Dupixent injection or related product use guidance.*
FDA Label Image

Image (Dupixent 36)

Image (Dupixent 36)
An instructional illustration showing a pair of hands demonstrating how to remove the cap from a syringe by pulling it straight off. The image focuses on the proper handling technique before administration.*
FDA Label Image

Image (Dupixent 37)

Image (Dupixent 37)
An instructional illustration showing a hand pinching the skin on the lower abdomen, demonstrating the proper site for injection, associated with Dupixent (dupilumab) administration.*
FDA Label Image

Image (Dupixent 38)

Image (Dupixent 38)
An instructional illustration showing a hand holding a Dupixent autoinjector at a 45-degree angle to the skin, with an arrow indicating the direction to press down for injection. The image visually demonstrates the correct angle and motion for administering the subcutaneous injection with the autoinjector.*
FDA Label Image

Image (Dupixent 39)

Image (Dupixent 39)
An instructional illustration showing a person administering an injection with a syringe into the abdominal area, highlighting the injection technique with a downward arrow indicating pressing the syringe into the skin.*
FDA Label Image

Image (Dupixent 40)

Image (Dupixent 40)
An illustration showing a hand holding a Dupixent prefilled syringe with the needle cap being removed by pulling it straight off, positioned above the other hand preparing for injection. The image demonstrates the correct step for needle cap removal prior to administration.*
FDA Label Image

Image (Dupixent 41)

Image (Dupixent 41)
An instructional illustration showing a hand disposing of a syringe by placing the needle cap into a red sharps disposal container. The diagram labels the syringe, needle cap, and the sharps disposal container.*
FDA Label Image

Logo (Dupixent 41a)

FDA Label Image

Image (Dupixent 42)

Image (Dupixent 42)
Illustration showing the Dupixent 300 mg/2 mL prefilled syringe before and after injection. The left image displays the green cap, medicine window, and label. The right image shows the syringe with the green cap removed and a yellow needle cover visible, indicating injection completion with a yellow window.*
FDA Label Image

Image (Dupixent 43)

Image (Dupixent 43)
Instructional diagram showing items recommended for use with the DUPIXENT pre-filled pen, including one alcohol wipe, one cotton ball or gauze, and a sharps disposal container. A note indicates these items are not included in the carton.*
FDA Label Image

Image (Dupixent 44)

Image (Dupixent 44)
An instructional illustration showing a Dupixent prefilled syringe labeled 300 mg/2 mL by Sanofi-Aventis U.S. LLC. The image highlights the syringe window with a yellow indicator and a red X mark, indicating a caution or error related to the window display.*
FDA Label Image

Image (Dupixent 45)

Image (Dupixent 45)
Packaging label of Dupixent 300 mg/2 mL prefilled syringe by Sanofi-Aventis U.S. LLC. The label shows the product name and strength prominently on a white background with green accents, including an image of the syringe. Text above instructs to 'Check the Medicine and Dose.'*
FDA Label Image

Image (Dupixent 46)

Image (Dupixent 46)
Dupixent 300 mg/2 mL single-dose prefilled syringe packaging label from Sanofi-Aventis U.S. LLC. The label displays the product name, strength, and dosage form along with usage instructions depicted in icons showing syringe handling steps. The background is predominantly white with colored sections and text for clarity.*
FDA Label Image

Image (Dupixent 48)

Image (Dupixent 48)
Dupixent 200 mg/1.14 mL single-dose prefilled syringe packaging label by Sanofi-Aventis U.S. LLC. The label includes the product name, strength, and dosage form with a simple design featuring blue and yellow accent colors on a white background.*
FDA Label Image

Image (Dupixent 49)

Image (Dupixent 49)
An instructional illustration showing a labeled 'Check Window' feature with a green check mark. The graphic highlights the importance of inspecting a specific window area, likely on a medication device, as part of its usage instructions.*
FDA Label Image

Image (Dupixent 50)

Image (Dupixent 50)
Dupixent 300 mg/2 mL, a single-dose prefilled syringe for injection, displayed with a clear plastic cap covering the needle. The syringe is marked with calibrated dosing lines and printed labeling indicating the product name, strength, and manufacturer, Sanofi-Aventis U.S. LLC.*
FDA Label Image

Image (Dupixent 51)

Image (Dupixent 51)
Illustration of a clock face showing a 45-minute interval, with a portion of the clock shaded to indicate the elapsed time. The text '45 minutes' is displayed prominently in the center of the clock.*
FDA Label Image

Image (Dupixent 52)

Image (Dupixent 52)
An illustration showing hands being washed under a running water faucet, depicting proper handwashing technique.*
FDA Label Image

Image (Dupixent 53)

Image (Dupixent 53)
Dupixent 300 mg/2 mL single-dose prefilled syringe packaging label by Sanofi-Aventis U.S. LLC. The label includes the brand name Dupixent, the strength 300 mg/2 mL, and features a colored design with orange and teal elements. Product and manufacturer information is presented clearly on the packaging.*
FDA Label Image

Image (Dupixent 54)

Image (Dupixent 54)
Dupixent 200 mg/1.14 mL single-dose prefilled syringe packaging label by Sanofi-Aventis U.S. LLC. The label highlights the brand name, dose strength, and prefilled syringe dosage form. It includes storage instructions, administration details, and barcodes on the packaging.*
FDA Label Image

Image (Dupixent 55)

Image (Dupixent 55)
Illustration showing recommended injection sites for Dupixent self-injection and caregiver injection. Self-injection sites include the abdomen (away from the navel) and front thighs. Caregiver injection sites include the outer upper arm, abdomen, and front thighs, highlighted in blue on body diagrams.*
FDA Label Image

Image (Dupixent 56)

Image (Dupixent 56)
Dupixent 200 mg/1.14 mL single-dose prefilled syringe carton label showing brand name, strength, dosage form, and manufacturer Sanofi-Aventis U.S. LLC. The label is white with purple and orange accents, including identification elements such as barcode and drug information.*
FDA Label Image

Image (Dupixent 57)

Image (Dupixent 57)
An instructional illustration showing a hand holding a small rectangular packet or patch positioned above an area of skin on the upper arm, indicating application of a product to the skin.*
FDA Label Image

Image (Dupixent 58)

Image (Dupixent 58)
Dupixent 300 mg/2 mL single-dose prefilled syringe label from Sanofi-Aventis U.S. LLC. The label clearly shows the brand name Dupixent, strength, dosage form as a prefilled syringe, and labeler information. It includes graphical elements and caution statements typical for injectable drug products.*
FDA Label Image

Image (Dupixent 59)

Image (Dupixent 59)
An instructional diagram showing how to remove the green cap from a Dupixent prefilled syringe. It highlights pulling the green cap straight off and warns not to touch the needle inside or remove the yellow safety cover. The syringe is labeled with the partial name 'DUPIXE.'*
FDA Label Image

Image (Dupixent 60)

Image (Dupixent 60)
An instructional illustration showing a hand holding a Dupixent autoinjector device at a 90-degree angle against a surface. The image highlights the autoinjector's window, indicating where to look during use. The diagram demonstrates correct positioning for administration.*
FDA Label Image

Image (Dupixent 61)

Image (Dupixent 61)
An instructional diagram showing how to use a Dupixent injection device. It illustrates the steps: pressing for the first click, watching the window turn yellow after the second click, and counting steadily up to five seconds while pressing to ensure proper injection.*
FDA Label Image

Image (Dupixent 62)

Image (Dupixent 62)
Dupixent 200 mg/1.14 mL subcutaneous injection single-dose pre-filled syringe carton label. The label prominently displays the product name, strength, dosage form, and pre-filled syringe illustration. Labeler is Sanofi-Aventis U.S. LLC. The packaging also includes a lot number/date section and needle safety descriptions.*
FDA Label Image

Image (Dupixent 63)

Image (Dupixent 63)
Dupixent 200 mg/1.14 mL injectable solution vial label, showing the product name, strength, dosage form as a single-dose vial, and the labeler Sanofi-Aventis U.S. LLC. The label features dosage and packaging details with distinctive brand and regulatory text.*
FDA Label Image

Image (Dupixent 64)

Image (Dupixent 64)
An instructional illustration showing a hand holding a Dupixent injection pen. The pen is positioned vertically above the injection site with an orange upward arrow indicating it is being lifted away after use.*
FDA Label Image

Image (Dupixent 65)

Image (Dupixent 65)
Dupixent 200 mg/1.14 mL single-dose vial packaging label from Sanofi-Aventis U.S. LLC. The label displays the product name, strength, and dosage form prominently along with usage instructions and safety warnings on the vial label.*
FDA Label Image

Image (Dupixent 66)

Image (Dupixent 66)
Dupixent 200 mg/1.14 mL and 300 mg/2 mL prefilled syringes by Sanofi-Aventis U.S. LLC. The image shows two individual glass syringes with clear barrels, needle caps, and black plungers. Each syringe is labeled with dosage and brand information clearly visible on the barrel.*
FDA Label Image

Image (Dupixent 67)

Image (Dupixent 67)
Dupixent 200 mg/1.14 mL prefilled syringe packaging label by Sanofi-Aventis U.S. LLC. The carton displays the brand name Dupixent prominently at the top, with the dose and strength indicated below. The label includes the dosage form as a prefilled syringe and relevant usage information in standard pharmaceutical label format.*
FDA Label Image

Image (Dupixent 68)

Image (Dupixent 68)
An instructional illustration showing a pre-filled pen with a green cap being held above a sharps disposal container. The image includes a warning in red text advising not to put the green cap back on the pre-filled pen. This corresponds to Dupixent pre-filled pen usage guidance.*
FDA Label Image

Logo (Dupixent 68a)

FDA Label Image

Image (Dupixent 69)

Image (Dupixent 69)
Instructional illustration showing the Dupixent 200 mg/1.14 mL injection pen before and after injection. Labels identify components such as the yellow cap, window, medicine, label, orange needle cover, and indicate that a yellow window signifies injection completion.*
FDA Label Image

Image (Dupixent 70)

Image (Dupixent 70)
Illustration showing the contents and additional items for the Dupixent pre-filled pen, including the pen device, one alcohol wipe, one cotton ball or gauze, and a sharps disposal container, with a note that these items are not included in the carton.*
FDA Label Image

Image (Dupixent 71)

Image (Dupixent 71)
Dupixent 200 mg/1.14 mL prefilled syringe label. The syringe shows dosage strength and the brand name with a yellow arrow on one end and an orange band on the other end. Labeler is Sanofi-Aventis U.S. LLC.*
FDA Label Image

Image (Dupixent 72)

Image (Dupixent 72)
An instructional illustration showing a close-up of a pen injector's window with a red X mark, indicating an incorrect position or usage of the Dupixent pen injector.*
FDA Label Image

Image (Dupixent 73)

Image (Dupixent 73)
An instructional illustration showing two views of a Dupixent prefilled syringe labeled 200 mg/1.14 mL. The top view highlights checking the medicine and dose on the syringe label. The bottom view indicates where to find the expiration date on the syringe label. Arrows and text guide proper inspection before use.*
FDA Label Image

Image (Dupixent 74)

FDA Label Image

Image (Dupixent 76)

FDA Label Image

Image (Dupixent 77)

Image (Dupixent 77)
An illustration showing a close-up of a device window labeled as the "Check Window." The window displays a small visual indicator with a checkmark next to it, suggesting confirmation or readiness status.*
FDA Label Image

Image (Dupixent 78)

FDA Label Image

Image (Dupixent 79)

Image (Dupixent 79)
Illustration of a clock face showing "30 minutes" in the center, with an orange circular outline and simple tick marks to indicate time intervals.*
FDA Label Image

Image (Dupixent 80)

Image (Dupixent 80)
Illustration depicting hand washing under a faucet with running water, showing one hand rinsing the other. The graphic emphasizes hygiene practices.*
FDA Label Image

Image (Dupixent 81)

FDA Label Image

Image (Dupixent 82)

FDA Label Image

Image (Dupixent 83)

Image (Dupixent 83)
Illustration showing recommended injection sites for Dupixent self-injection and caregiver injection. Self-injection sites are highlighted on the front of the thighs and abdomen. Caregiver injection sites include the back of the upper arms, the abdomen, and the front of the thighs.*
FDA Label Image

Image (Dupixent 84)

FDA Label Image

Image (Dupixent 85)

Image (Dupixent 85)
An instructional illustration showing a hand applying a small adhesive patch or dressing to the lower abdominal area, suggesting a step in the administration or care process related to the product Dupixent.*
FDA Label Image

Image (Dupixent 86)

FDA Label Image

Image (Dupixent 87)

Image (Dupixent 87)
Instructional illustration showing how to use a Dupixent autoinjector by pulling the yellow cap straight off, revealing the needle inside. The image emphasizes correct removal without twisting or bending the cap.*
FDA Label Image

Image (Dupixent 88)

Image (Dupixent 88)
An instructional diagram showing proper use of a prefilled syringe for Dupixent, depicting a hand holding the syringe at a 90-degree angle to the skin. The image instructs to pinch the skin and look at the window on the syringe before injection.*
FDA Label Image

Image (Dupixent 89)

Image (Dupixent 89)
An instructional illustration showing how to use a Dupixent prefilled injector. It demonstrates pressing down the injector until the first click, watching for the window to turn yellow with the second click, and counting to five while continuing to press to complete the injection process.*
FDA Label Image

Image (Dupixent 90)

FDA Label Image

Image (Dupixent 91)

FDA Label Image

Image (Dupixent 92)

Image (Dupixent 92)
Illustration showing a hand holding a Dupixent injection pen. The image depicts an upward arrow indicating the injection pen should be lifted or removed after use, highlighting part of the administration process for Dupixent 200 mg or 300 mg injection by Sanofi-Aventis U.S. LLC.*
FDA Label Image

Image (Dupixent 93)

FDA Label Image

Image (Dupixent 94)

FDA Label Image

Image (Dupixent 95)

FDA Label Image

Image (Dupixent 96)

Image (Dupixent 96)
An instructional illustration showing a hand holding a Dupixent pre-filled pen with a yellow cap. The pen is being disposed of into a red sharps container, with a warning in red and black text stating, 'Do not put the Yellow Cap back on.' This image guides safe disposal of the Dupixent pre-filled pen.*
FDA Label Image

Logo (Dupixent 96a)

FDA Label Image

Image (Dupixent 97)

Image (Dupixent 97)
An instructional diagram showing a syringe labeled Dupixent before and after use. Before use includes parts such as the plunger rod, finger grip, viewing window, syringe body, needle, and needle cap. After use shows the plunger rod extended down, with the needle shield covering the needle.*
FDA Label Image

Image (Dupixent 98)

FDA Label Image

Image (Dupixent 99)

FDA Label Image

Image (Dupixent 100)

Image (Dupixent 100)
An instructional illustration showing a hand holding a prefilled syringe inside an open box with compartments for other contents. The image is likely related to preparation or administration of a prefilled syringe product, such as Dupixent, but does not contain text or dosage details.*
FDA Label Image

Image (Dupixent 101)

Image (Dupixent 101)
An instructional diagram showing items for administration of Dupixent pre-filled syringe. It depicts a pre-filled syringe and lists necessary supplies: 1 alcohol wipe, 1 cotton ball or gauze, and a sharps disposal container.*
FDA Label Image

Image (Dupixent 102)

FDA Label Image

Image (Dupixent 103)

Image (Dupixent 103)
An instructional diagram showing a Dupixent injection device or syringe with a focus on the label area. The diagram highlights where to find the lot number and expiration date on the device, including arrows pointing to these label details for user reference.*
FDA Label Image

Image (Dupixent 104)

FDA Label Image

Image (Dupixent 105)

Image (Dupixent 105)
An instructional diagram showing a Dupixent prefilled syringe with a labeled viewing window. The image points to the window area where the lot number and expiration date are displayed on the syringe barrel for verification before use.*
FDA Label Image

Image (Dupixent 106)

FDA Label Image

Image (Dupixent 107)

FDA Label Image

Image (Dupixent 108)

FDA Label Image

Image (Dupixent 109)

Image (Dupixent 109)
An instructional illustration showing a syringe with a timer indicating a 30-minute period. The image likely depicts timing guidance related to the use of the syringe.*
FDA Label Image

Image (Dupixent 110)

FDA Label Image

Image (Dupixent 111)

Image (Dupixent 111)
An illustration showing body areas for Dupixent injection by caregiver only, highlighting the outer upper arms, abdomen (avoiding the navel), and front of the thighs as injection sites.*
FDA Label Image

Image (Dupixent 112)

FDA Label Image

Image (Dupixent 113)

Image (Dupixent 113)
An illustration showing a hand applying a small square patch to the lower abdomen area, likely demonstrating the placement of a transdermal patch or similar topical drug delivery system.*
FDA Label Image

Image (Dupixent 114)

FDA Label Image

Image (Dupixent 115)

FDA Label Image

Image (Dupixent 116)

Image (Dupixent 116)
An instructional illustration showing two hands preparing a syringe, with arrows indicating the removal of a cap or protective cover before use. The image likely relates to administration guidance for Dupixent injectable product.*
FDA Label Image

Image (Dupixent 117)

Image (Dupixent 117)
An instructional illustration showing a hand pinching the skin on the lower abdomen, likely demonstrating a site for subcutaneous injection.*
FDA Label Image

Image (Dupixent 118)

Image (Dupixent 118)
Instructional illustration showing how to hold and inject Dupixent at a 45-degree angle, demonstrating the correct technique for administering the injectable medication.*
FDA Label Image

Image (Dupixent 119)

Image (Dupixent 119)
An instructional illustration showing a hand holding and preparing a Dupixent pre-filled syringe for injection at the abdomen area. The image depicts proper hand placement and site selection for subcutaneous injection of Dupixent, a medication by Sanofi-Aventis U.S. LLC available in strengths 200 mg/1.14 mL and 300 mg/2 mL.*
FDA Label Image

Image (Dupixent 120)

FDA Label Image

Image (Dupixent 121)

FDA Label Image

Image (Dupixent 122)

Image (Dupixent 122)
An instructional illustration showing the use of the Dupixent prefilled syringe for subcutaneous injection. It depicts a hand holding the syringe positioned near the thigh, with an arrow indicating the direction of injection.*
FDA Label Image

Image (Dupixent 123)

FDA Label Image

Image (Dupixent 124)

FDA Label Image

Image (Dupixent 125)

Image (Dupixent 125)
An instructional illustration showing a hand disposing of a syringe with a needle cap into a red sharps disposal container. The syringe and needle cap are clearly labeled, emphasizing proper disposal method for Dupixent injection materials.*
FDA Label Image

Logo (Dupixent 125a)

FDA Label Image

Principal Display Panel (300 mg/2 mL Syringe Carton)

Principal Display Panel (300 mg/2 mL Syringe Carton)
Dupixent (dupilumab) Injection carton for 300 mg/2 mL strength. The package contains 2 single-dose pre-filled syringes with needle shield for subcutaneous use only. Label shows storage instructions requiring refrigeration at 36°F to 46°F (2°C to 8°C) and warns against freezing and exposure to heat or direct sunlight. Manufactured by Sanofi Genzyme and Regeneron, labeled Rx Only. Includes barcode and space for serialization and distribution information.*
FDA Label Image

Principal Display Panel (200 mg/1.14 mL Syringe Carton)

Principal Display Panel (200 mg/1.14 mL Syringe Carton)
Dupixent (dupilumab) Injection 200 mg/1.14 mL single-dose pre-filled syringes with needle shield carton. The packaging is teal with white and orange details, indicating the strength 200 mg/1.14 mL (175 mg/mL). It specifies for subcutaneous use only and contains 2 pre-filled syringes. Labeler names Sanofi Genzyme and Regeneron are shown. Storage instructions and handling warnings are included on the carton.*
FDA Label Image

Principal Display Panel (300 mg/2 mL Pen Carton)

Principal Display Panel (300 mg/2 mL Pen Carton)
Packaging label for Dupixent 300 mg/2 mL (150 mg/mL) injection in a single-dose pre-filled pen. The carton contains 2 pre-filled pens. Labeler is Sanofi-Aventis U.S. LLC. Storage instructions advise refrigeration at 36° to 46°F (2° to 8°C), avoiding freezing, heat, and direct sunlight. Includes a barcode and safety warnings.*
FDA Label Image

Principal Display Panel (200 mg/1.14 mL Pen Carton)

Principal Display Panel (200 mg/1.14 mL Pen Carton)
Dupixent 200 mg/1.14 mL (175 mg/mL) injection single-dose pre-filled pen carton label. The label shows that the carton contains 2 single-dose pre-filled pens of dupilumab for subcutaneous use. It includes storage instructions, dosage form, and manufacturer names Sanofi Genzyme and Regeneron. The design features orange and green arrow graphics, with detailed handling and safety information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.